Joyzyme Group Limited has released its latest Company Information Sheet, dated 31 August 2026, highlighting key metrics and governance details following its 13 December 2018 debut on Hong Kong’s GEM Board.

Share Capital and Trading Parameters • Outstanding Shares: 515.47 million ordinary shares, each with a par value of HK$0.01. • Board Lot Size: 8,000 shares.

Ownership Structure • Controlling Shareholder: Anselme Limited holds 259.52 million shares, translating to a 50.35% stake. Anselme is wholly owned by Executive Director and Chairman Dr Zhou Xunyong, who is deemed to hold the same interest. • No other substantial shareholders were disclosed.

Equity Incentives • Share Options: On 9 April 2020, the company granted 26.01 million options at an exercise price of HK$0.125. To date, 19.00 million have been exercised and 7.01 million forfeited, leaving no outstanding options under this grant. All options are exercisable until 8 April 2030. • No warrants or guaranteed debt securities are outstanding.

Corporate Governance • Board Composition: Four Executive Directors (including Dr Zhou), one Non-Executive Director, and three Independent Non-Executive Directors. • Auditor: Forvis Mazars CPA Limited. • Sponsor at listing: RHB Capital Hong Kong Limited.

Business Focus Joyzyme specializes in the research, development, manufacture, and sale of in-vitro diagnostic reagents, auxiliary reproductive supplies and equipment, and healthcare products in mainland China.

Organizational Footprint • Place of Incorporation: Cayman Islands. • Main Offices: Hong Kong (Chinachem Golden Plaza, Kowloon) and Shenzhen, PRC. • Financial Year-End: 31 December.

No other group companies are listed on the Hong Kong bourses, and no additional securities beyond the ordinary shares and disclosed options are outstanding.